Thirty advanced ovarian cancer patients have been treated with sequential multimodality treatment including primary surgery, cisplatin or carboplatin-based polichemotherapy, second-look laparotomy followed by abdominopelvic irradiation (moving strip or open-field technique). Toxicity related to the combined treatment was acceptable: only three patients failed to complete and two patients delayed the prescribed course of radiotherapy because of acute myelosuppression or gastroenteric disturbances. One patient without evidence of disease required laparotomy for bowel obstruction one month after completion of radiotherapy. No other chronic toxicity of clinical significance has been observed. Actuarial three-year survival significantly correlated with residual disease at the start of radiotherapy: no residuum, 100\%, microscopic disease, 52\%; less than 2 cm macroscopic disease, 27.4\% (P less than 0.05), whereas recurrences were less frequent only in the group of pathological complete responders (3/9) compared to patients with limited disease (6/11 with micro and 7/10 with macroscopic residuum). In conclusion radiotherapy following surgery and chemotherapy is not associated to serious morbidity but its value in improving progression-free survival rates has to be tested in randomized trials.
|Data di pubblicazione:||1991|
|Titolo:||Abdominopelvic radiotherapy following surgery and chemotherapy in advanced ovarian cancer.|
|Autore/i:||S. Chiara;M. Orsatti;P. Franzone;D. Scarpati;M. Bruzzone;L. Repetto;V. Vitale;P. F. Conte;R. Rosso|
|Codice identificativo Scopus:||2-s2.0-0026248669|
|Citazione:||Abdominopelvic radiotherapy following surgery and chemotherapy in advanced ovarian cancer / S. Chiara;M. Orsatti;P. Franzone;D. Scarpati;M. Bruzzone;L. Repetto;V. Vitale;P. F. Conte;R. Rosso. - In: CLINICAL ONCOLOGY. - ISSN 0936-6555. - STAMPA. - 3(1991), pp. 340-344.|
|Tipologia||Articolo su rivista|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris